Annals of Surgical Oncology

, Volume 19, Issue 5, pp 1477–1483

Six-Year Analysis of Treatment-Related Toxicities in Patients Treated with Accelerated Partial Breast Irradiation on the American Society of Breast Surgeons MammoSite Breast Brachytherapy Registry Trial

  • A. J. Khan
  • Douglas Arthur
  • F. Vicini
  • P. Beitsch
  • H. Kuerer
  • S. Goyal
  • Maureen Lyden
  • B. G. Haffty
Breast Oncology

DOI: 10.1245/s10434-011-2133-1

Cite this article as:
Khan, A.J., Arthur, D., Vicini, F. et al. Ann Surg Oncol (2012) 19: 1477. doi:10.1245/s10434-011-2133-1

Abstract

Background

The American Society of Breast Surgeons (ASBrS) enrolled women in a registry trial to prospectively study patients treated with the MammoSite RTS device. This report presents 6-year data on treatment-related toxicities from the trial.

Methods

A total of 1449 primary early-stage breast cancers were treated with accelerated partial breast irradiation (APBI) using the MammoSite device (34 Gy in 10 fractions) in 1440 women. Of these, 1255 case (87%) had invasive breast cancer (IBC) (median size = 10 mm) and 194 cases (13%) had ductal carcinoma in situ (DCIS) (median size = 8 mm). Median follow-up was 59 months. Fisher exact test was performed to correlate categorical covariates with toxicity.

Results

Breast seromas were reported in 28% of cases (35.5% with open cavity and 21.7% with closed cavity placement). Also, 13% of all treated breasts developed symptomatic seromas, and 77% of these seromas developed during the 1st year after treatment. There were 172 cases (11.9%) that required drainage to correct. Use of chemotherapy and balloon fill >50 cc were associated with the development of symptomatic seromas. Also, 2.3% of patients developed fat necrosis (FN). The incidence of FN during years 1 and 2 were 0.9% and 0.8%, respectively. Seroma formation, use of hormonal therapy, breast infection, and A/B cup size were associated with fat necrosis. There were 138 infections (9.5%) recorded; 98% occurred during the 1st year after treatment. Chemotherapy and seroma formation were associated with the development of infections.

Conclusions

Treatment-related toxicities 6 years after treatment with APBI using the MammoSite device are similar to those reported with other forms of APBI with similar follow-up.

Copyright information

© Society of Surgical Oncology 2011

Authors and Affiliations

  • A. J. Khan
    • 1
  • Douglas Arthur
    • 2
  • F. Vicini
    • 3
  • P. Beitsch
    • 4
  • H. Kuerer
    • 5
  • S. Goyal
    • 1
  • Maureen Lyden
    • 6
  • B. G. Haffty
    • 1
  1. 1.Department of Radiation OncologyCancer Institute of New JerseyNew BrunswickUSA
  2. 2.Department of Radiation OncologyVirginia Commonwealth UniversityRichmondUSA
  3. 3.Department of Radiation OncologyWilliam Beaumont HospitalRoyal OakUSA
  4. 4.Department of SurgeryDallas Breast CenterDallasUSA
  5. 5.Department of SurgeryM. D. Anderson Cancer CenterHoustonUSA
  6. 6.BioStat International, Inc.TampaUSA